Cipla Ltd (CIPLA) — Announcement | 31 August 2026

· BSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Cipla signs exclusive licensing deal for TQB2102 ADC with SBP Group
💡 Investor Takeaway
This partnership expands Cipla’s oncology pipeline with a high-potential ADC, potentially driving future growth in emerging markets.

Cipla announced on August 31, 2026 that it signed an exclusive licensing agreement with SBP Group’s subsidiary CTTQ to develop and commercialize TQB2102, a HER2 bispecific ADC, in India, South Africa, and five emerging markets, leveraging Cipla’s regulatory and commercial infrastructure to accelerate patient access.

📄 View Original Announcement (PDF)

About Cipla Ltd (CIPLA)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹1,14,390.9 Cr P/E: 33.9 ROE: 9.8% ROCE: 13.2% Div Yield: 0.92%

View full CIPLA stock details →

📡 Get AI alerts when CIPLA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track CIPLA — Free

📊 More CIPLA filings

See all CIPLA filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when CIPLA files new disclosures

Track CIPLA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track CIPLA — Free

Free account · 2 AI queries/day